Anti-angiogenic proteins and methods of use thereof
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorRaghuram Kalluri
Life of this patent
Estimating the term…
Abstract
Proteins with anti-angiogenic properties are disclosed, and methods of using those proteins to inhibit angiogenesis.
Claims44
An isolated protein, selected from the group consisting of:
- the NC1 domain of the α1 chain of Type IV collagen, the NC1 domain of the α2 chain of Type IV collagen, or the NC1 domain of the α3 chain of Type IV collagen, or a fragment, analog, derivative or mutant thereof, wherein the protein, fragment, analog, derivative or mutant thereof has anti-angiogenic properties.
A polypeptide comprising amino acid 2 to amino acid 125 of SEQ ID NO:10, the polypeptide having anti-angiogenic activity.
A polypeptide comprising amino acid 125 to amino acid 245 of SEQ ID NO:11, the polypeptide having anti-angiogenic activity.
An anti-angiogenic fragment of the NC1 domain of the α1 chain of Type IV collagen, the fragment made by the process of PCR cloning.
An anti-angiogenic fragment of the NC1 domain of the α2 chain of Type IV collagen, the fragment made by the process of PCR cloning.
An anti-angiogenic fragment of the NC1 domain of the α3 chain of Type IV collagen, the fragment made by the process of PCR cloning.
An anti-angiogenic fragment of the NC1 domain of the α1 chain of Type IV collagen, the fragment made by the process of Pseudomonas elastase digestion.
An anti-angiogenic fragment of the NC1 domain of the α2 chain of Type IV collagen, the fragment made by the process of Pseudomonas elastase digestion.
An anti-angiogenic fragment of the NC1 domain of the α3 chain of Type IV collagen, the fragment made by the process of Pseudomonas elastase digestion.
Dependencies are inferred from the claim text.